SciMed Solutions

Drug discovery is often imagined as a purely experimental process happening in the lab.

But today, many of the most important decisions happen inside a computer first.

In the latest episode of the SciMed Biotech Podcast, we sat down with Dr. Chuck Reynolds, founder of Gfree Bio, to discuss how computational chemistry is helping scientists design better drugs before they ever synthesize them.

We discuss how molecular modeling and docking simulations help scientists predict how drugs interact with proteins, guide medicinal chemistry decisions, and accelerate the iterative process of drug discovery. Chuck also shares how advances in computing power and machine learning are expanding what’s possible in computational drug design.

If you’re interested in the intersection of biotech, computational modeling, and drug discovery, this episode provides a great overview of how these tools are shaping modern pharma R&D.

Listen to the episode here: https://www.scimed.io/news/chuck-reynolds-gfree-bio

Urgent care didn’t grow simply because it was convenient. It grew because patients needed another option when they could not quickly access primary care.

On the SciMed Biotech Podcast we spoke with Paul Nanda, Chief Medical Officer of TGH Urgent Care powered by Fast Track, about how urgent care emerged to fill that gap and how technology is now pushing the model even further.

Remote diagnostic tools that cost only a few hundred dollars can now help physicians examine a patient’s eyes, ears, throat, heart, lungs, and vital signs from a distance. What once required expensive telemedicine kiosks is becoming something patients can use right from home.

It is a reminder that urgent care is no longer only a place you go. It is gradually becoming a more distributed way to deliver care while still maintaining quality clinical exams.

Listen in on our website 🎧
https://scimed.io/news/paul-nanda-tgh-urgent-care-official

SciMed Biotech Podcast with Dr. Paul Nanda — SciMed Dr. Paul Nanda has delivered babies in Zimbabwe, supported displaced Ukrainian refugees in Warsaw, and now leads urgent care initiatives across the Tampa Bay region. In this episode, he shares how his global medical missions—from Haiti to New Zealand—have shaped his perspective on healthcare acc...

Most cell therapies struggle in solid tumors for the same reasons: limited pe*******on, rapid exhaustion, and high relapse rates. In this episode of the SciMed Biotech Podcast, I sat down with Shubhranshu Gupta, PhD, CEO & Founder of Immumem Therapeutics, to unpack how engineering true immune memory into TN/NK cells could change what’s possible in solid tumor immunotherapy.

We get into why current cell therapies break down in the tumor microenvironment, how ECM barriers and metabolic exhaustion limit persistence, and how Immumem is training immune cells to behave more like memory cells rather than short-lived effectors. Shubhranshu also shares how iPSC-derived cells enable scalable, off-the-shelf approaches, and how machine learning is being used to better connect ex vivo results with predicted in vivo performance.

Listen to the full episode here:
https://www.scimed.io/news/shubhranshu-gupta-immumem-therapeutics

“Personalized repetitive TMS uses spectral EEG data to guide stimulation across multiple cortical regions, and we update the protocol weekly based on quantitative measurements..."

In this episode, Keerthy Sunder explains how neuromodulation is evolving beyond fixed-target TMS. Instead of stimulating a single location with a static protocol, spectral EEG and weekly data inputs allow clinicians to adjust frequency, coil position, and cortical targets dynamically — creating a measurement-driven pathway for treatment-resistant conditions.

We discuss what this means for psychiatry as a field: the move from “one-size-fits-all” interventions toward individualized neurocircuitry-based care, and how these methods are being adopted in clinical environments today.

Listen to the full discussion on the SciMed website: https://www.scimed.io/news/keerthy-sunder